Tikun Europe takes advantage of one of the most reputable and trusted brands among the medical cannabis industry, the Tikun Olam Israel. Tikun Europe has immediate access to a great track-record of clinical research, know-how and awards for its special production of strains.
Therefore the extensive patient treatment database of over 30.000 patients offers Tikun Europe the capability to develop and provide high quality medical cannabis products.
Tikun is dedicated to provide patients’ treatments, wellness, and overall quality of life.
Our mission is to bring cure and alleviation providing evidence based medical cannabis treatment worldwide.
This is easily achieved by taking advantage of our extensive know-how, long-term experience and the wide range of activities which include the following sections:
Journal of Autism and Developmental Disorders, 2018
A retrospective study assessing the tolerability and efficacy of CBD-rich cannabis in children with ASD.
Scientific Reports, 2019
This observational study assessed the safety and efficacy of medical cannabis for the treatment of autism spectrum disorders (ASD), analyzing the change in symptoms after six months of using our CBD-rich cannabis oil.
Journal of Child Neurology, 2018
A clinical random trial examining the effects of Avidekel oil on dystonia and spasticity in children who suffer from cerebral palsy or genetic impairment. Most participants reported significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and quality of life.
Clinical Gastroenterology & Hepatology, 2011
In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results, with 45% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed.
The Israel Medical Association Journal, 2013
This retrospective study observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).
Safety And Efficacy Of Medical Cannabis In Fibromyalgia
Publisher: Journal of Clinical Medicine, 2019
This observational study investigated the characteristics, safety, and effectiveness of medical cannabis therapy for fibromyalgia. Patients studied were referred to cannabis after receiving traditional treatment for at least a year without improvement. The change in symptoms and quality of life was measured after six months of treatment.
Avidekel Cannabis Extracts And Cannabidiol Are As Efficient As Copaxone In Suppressing EAE In SJS/J Mice
This study compared the efficacy of purified CBD, extracts of CBD-rich Avidekel, and Copaxone (glatiramer acetate), an immunosuppressive medication that is used to alleviate the symptoms of multiple sclerosis (MS).
Overcoming The Bell-Shaped Dose-Response Of Cannabidiol By Using Cannabis Extract Enriched In Cannabidiol
Pharmacology & Pharmacy, 2015
This laboratory study was conducted on rodents to examine the effect of full-plant cannabis extract on inflammation and pain, in comparison with isolated CBD and commercial anti-inflammatory and anti-nociceptive drugs. Isolated CBD has been shown to have a bell-shaped dose-response, where healing is only observed within a very limited dose range, with no additional beneficial effect achieved at lower or higher doses. This trait of purified CBD poses challenges to clinical use; thus, this study aimed to find a CBD source that eliminates the bell-shaped dose response – and succeeded with Avidekel.
Prospective Analysis Of Safety And Efficacy Of Medical Cannabis In Large Unselected Population Of Patients With Cancer
European Journal of Internal Medicine, 2018
This study analyzed the data routinely collected as part of the treatment program of cancer patients treated with medical cannabis between 2015 and 2017. The most frequent types of cancer were breast (20.7%), lung (13.6%), pancreatic (8.1%) and colorectal (7.9%), and 51.2% of patients were at Stage 4. The main symptoms requiring therapy were sleep problems (78.4%), pain (77.7%; median intensity 8/10), weakness (72.7%), nausea (64.6%) and lack of appetite (48.9%). The study concluded that cannabis is a well-tolerated, effective and safe option to help patients cope with cancer-related symptoms.
Epidemiological Characteristics, Safety And Efficacy Of Medical Cannabis In The Elderly
European Journal of Internal Medicine, 2018
A prospective study that analyzed the use of cannabis treatment in the elderly, measuring for pain intensity, quality of life, and adverse effects at six months follow-up. The most common indications for cannabis treatment were pain (66.6%) and cancer (60.8%). The study found that the therapeutic use of cannabis is safe and efficacious in the elderly population.
Medical Cannabis In Parkinson’s Disease
Clinical Neuropharmacology, 2017
A retrospective questionnaire-based survey that examined the effects of cannabis on the motor and non-motor symptoms of patients with Parkinson’s Disease. The mean age of the patients was 64.2 +/- 10.8 years, the mean disease duration was 10.8 +/- 8.3 years, and the duration of cannabis use was 19.1 +/- 17 months.
Single Center Experience With Medical Cannabis In Gilles De La Tourette Syndrome
Parkinsonism and Related Disorders, 2018
This study was conducted to assess the response and benefits of using cannabis to treat Tourette Syndrome.
Made by Nature. Backed by Science.